AstraZeneca CEO Pascal Soriot said it’s time for the U.S. to start paying more reasonable prices for new drugs, which are closer to what other wealthy countries pay, in a rare stance in an industry ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

Speaking from Astra's offices in New York, Sir Pascal Soriot (pictured) said it was 'global', but it was 'very much rooted ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 billion in manufacturing.

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...

AstraZeneca said it is investing $50 billion in US manufacturing by 2030, following the lead of big pharma peers that have ...

AstraZeneca CEO Pascal Soriot is plotting a shift of the company’s primary stock listing from the London to the U.S., according to The Times.

In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...